Price$16.54-0.48 (-2.78%)
01:30 PM04:15 PM
News · 26 weeks60+150%
2026-03-012026-08-23
Mix3190d
- SEC Filings13(42%)
- Insider11(35%)
- Other5(16%)
- Analyst2(6%)
Latest news
25 items- SECSEC Form 8-K filed by Climb Bio Inc.8-K - Climb Bio, Inc. (0001768446) (Filer)
- SECSEC Form 10-Q filed by Climb Bio Inc.10-Q - Climb Bio, Inc. (0001768446) (Filer)
- SECClimb Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Climb Bio, Inc. (0001768446) (Filer)
- PRClimb Bio Reports Second Quarter 2026 Financial Results and Provides Business UpdatesCLYM116 Phase 1 data in healthy volunteers to be presented at R&D Spotlight Event on September 3, 2026 Anticipate CLYM116 Phase 2 trial in IgA nephropathy to initiate dosing in Q3 2026 Budoprutug clinical programs continue to advance, with data expected from pMN, ITP, and SLE studies in Q4 2026 Financing extends cash runway into the second half of 2028 WELLESLEY HILLS, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the second quarter ended June 30, 2026, and provided business updates. "2026 is proving to be a defining
- ANALYSTRBC Capital Mkts initiated coverage on Climb Bio with a new price targetRBC Capital Mkts initiated coverage of Climb Bio with a rating of Outperform and set a new price target of $23.00
- SECSEC Form SCHEDULE 13G filed by Climb Bio Inc.SCHEDULE 13G - Climb Bio, Inc. (0001768446) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Climb Bio Inc.SCHEDULE 13D/A - Climb Bio, Inc. (0001768446) (Subject)
- INSIDERSEC Form 4 filed by Director Ra Capital Management, L.P.4 - Climb Bio, Inc. (0001768446) (Issuer)
- INSIDERSEC Form 4 filed by Director Celebi Breanna Maurine4 - Climb Bio, Inc. (0001768446) (Issuer)
- INSIDERSEC Form 3 filed by new insider Celebi Breanna Maurine3 - Climb Bio, Inc. (0001768446) (Issuer)
- SECSEC Form 8-K filed by Climb Bio Inc.8-K - Climb Bio, Inc. (0001768446) (Filer)
- INSIDERPresident and CEO Brennan Aoife converted options into 68,750 shares and sold $406,979 worth of shares (30,902 units at $13.17) as part of a pre-agreed trading plan, increasing direct ownership by 76% to 87,731 units (SEC Form 4) (withholding tax)4 - Climb Bio, Inc. (0001768446) (Issuer)
- SECSEC Form 144 filed by Climb Bio Inc.144 - Climb Bio, Inc. (0001768446) (Subject)
- SECSEC Form 8-K filed by Climb Bio Inc.8-K - Climb Bio, Inc. (0001768446) (Filer)
- SECSEC Form 424B5 filed by Climb Bio Inc.424B5 - Climb Bio, Inc. (0001768446) (Filer)
- SECSEC Form 8-K filed by Climb Bio Inc.8-K - Climb Bio, Inc. (0001768446) (Filer)
- PRClimb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment ongoing in the high dose cohort, with additional data anticipated by year-end 2026 WELLESLEY HILLS, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced initial data from the ongoing Phase 1b portion of its Phase 1b/2a study evaluating budoprutug, an anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopenia (ITP) demonstrating an enc
- SECSEC Form EFFECT filed by Climb Bio Inc.EFFECT - Climb Bio, Inc. (0001768446) (Filer)
- SECSEC Form 424B3 filed by Climb Bio Inc.424B3 - Climb Bio, Inc. (0001768446) (Filer)
- INSIDERSEC Form 4 filed by Director Ra Capital Management, L.P.4 - Climb Bio, Inc. (0001768446) (Issuer)
- INSIDERSEC Form 4 filed by Director Levin Andrew David4 - Climb Bio, Inc. (0001768446) (Issuer)
- INSIDERSEC Form 4 filed by Director Drapkin Kimberlee C4 - Climb Bio, Inc. (0001768446) (Issuer)
- INSIDERSEC Form 4 filed by Director Williams Douglas E4 - Climb Bio, Inc. (0001768446) (Issuer)
- INSIDERSEC Form 4 filed by Director Cumbo Alexander4 - Climb Bio, Inc. (0001768446) (Issuer)
- INSIDERSEC Form 4 filed by Director Thomas Stephen Basil4 - Climb Bio, Inc. (0001768446) (Issuer)
CLYM FAQ
6 questionsWhere does CLYM stock trade?
Climb Bio Inc. (CLYM) is listed on NASDAQ.What sector and industry is CLYM in?
Climb Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Climb Bio Inc. go public?
Climb Bio Inc. (CLYM) completed its IPO in 2021.What are analysts saying about CLYM?
Climb Bio Inc. has had 8 recent analyst actions on file. The most recent action was from RBC Capital Mkts: Outperform with a $2300.00 price target on 2026-08-03. Recent price targets range from $1200.00 to $3500.00.What companies are similar to CLYM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CLYM side-by-side with any of them on Quantisnow.How can I track CLYM on Quantisnow?
Quantisnow aggregates Climb Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CLYM to receive live email and push alerts on every new disclosure.